A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07690319
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The aim of this study is to evaluate the effectiveness of early treatment with secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) and assess its impact on disease progression using data from multiple European data sources. All data will be sourced from existing non-interventional study primary data collection, registries, and hospital cohorts that captured information collected in routine clinical practice, prior to and independent of this study.

Key Dates

First listed
Jul 8, 2026
Start date
Oct 15, 2026
Status verified
Jun 2026
Primary completion
Mar 15, 2027
Completion
Mar 15, 2027

Study Design

Enrollment
186 participants (estimated)

Arms

  • Arm: Early Treatment Group
    Adult patients with moderate to severe HS, having up to 1 active tunnel (draining or non-draining) or up to 4 inflammatory lesions (abscess/nodules) at date of first secukinumab administration for HS treatment.
  • Arm: Late Treatment Group
    Adult patients with moderate to severe HS, having \>1 active tunnel or \>4 inflammatory lesions, at date of first secukinumab administration for HS treatment.

Primary Outcome Measure

Proportion of Patients Achieving 55% Reduction From Baseline in International Hidradenitis Suppurativa Severity Scoring System (IHS4-55) at 6 and 12 Months [ Time Frame: 6 and 12 months ]

Central Contacts

Find similar trials

Related Studies